Ledger.Open graph →
SEC Form D · filed February 24, 2017

Agilis Biotherapeutics, Inc

Offering
$23.3M
Sold
$12.7M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (12)

Mark J. Pykett · Cambridge, MAExec · DirectorAdrian Z. Stecyk · Dallas, TXDirectorG. H. Hall · Dallas, TXDirectorIan J. Ratcliffe · Cambridge, MADirectorAlexander M. Seaver · Dallas, TXDirectorRobert J. Hardie · Cambridge, MADirectorIan J. Ratcliffe · Cambridge, MADirectorMark J. Pykett · Cambridge, MAExec · DirectorAlexander M. Seaver · Dallas, TXDirectorRobert J. Hardie · Cambridge, MADirectorAdrian Z. Stecyk · Dallas, TXDirectorG. H. Hall · Dallas, TXDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗